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Abstract This study outlines trends in quality of delivered
non-Hodgkin’s lymphoma (NHL) care in the Netherlands be-
tween 2007 and 2011 and to what extend this was influenced
by the national Visible Care program, which aimed at increas-
ing transparency by providing insight into the quality of
healthcare. We analyzed data collected from medical records
in two observational studies, combined into 20 validated qual-
ity indicators (QIs) of which 6 were included in the national
program. A random sample of 771 patients, diagnosed with
NHL in 26 Dutch hospitals, was examined. Multilevel regres-
sion analyses were used to assess differences in quality of
NHL care and to provide insight into the effect of the national
program. We reported improved adherence to only 3 out of 6
QIs involved in the national program and none of the other 14
validated QIs. Improvement was shown for performance of all
recommended staging techniques (from 26 to 43 %), assess-
ment of International Prognostic Index (from 21 to 43 %), and
multidisciplinary discussion of patients (from 23 to 41 %). We
found limited improvement in quality of NHL care between
2007 and 2011; improvement potential (<80 % adherence)
was still present for 13 QIs. The national program seems to
have a small positive effect, but has not influenced all 20 indi-
cators which represent the most important, measurable parts in
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quality of NHL care. These results illustrate the need for tai-
lored implementation and quality improvement initiatives.
Keywords Non-Hodgkin’s lymphoma .
Quality of health care . Guidelines . Oncology .
Hematology . Transparency . Trends
Introduction
Non-Hodgkin’s lymphoma (NHL) affects over 300,000 peo-
ple worldwide each year [1]. NHL is listed in the top 10 of
most common cancers, with an estimated number of 69,000
new cases in the USA in 2013 [2] and responsible for 3 % of
all cancer deaths in the USA [3]. In the Netherlands, the inci-
dence of NHL is as high as 4000 newly diagnosed patients per
year. With an expanding and ageing population, these figures
are expected to increase. Well-organized and well-carried-out
diagnostics and treatments are essential to help patients in the
best possible way. Treatment of NHL is highly dependent on
the subtype, stage, and aggressiveness of the tumor. For the
most common subtypes, diffuse large B-cell lymphoma
(DLBCL) and follicular lymphoma (FL), chemotherapy com-
bined with immunotherapy (i.e., monoclonal antibody rituxi-
mab) has improved patient outcomes remarkably [4, 5].
Despite these improvements, the 5-year relative survival rate
for these patients is only 50–75 % [6].
To deliver high-quality care to patients diagnosed with
NHL, multidisciplinary evidence-based guidelines are devel-
oped to help professionals in their choices about diagnostics
and therapy [7–10]. Quality of care can be measured using
quality indicators, which are Bmeasurable elements of practice
performance for which there is evidence or consensus that
they can be used to assess the quality of care^ [11]. From
previous research, it is known that discrepancies exist between
NHL care delivered in daily practice and the (quality of) care
recommended in guidelines [12–14]. Gaining insight into
quality of delivered care is an upcoming phenomenon in
healthcare; hospitals and other healthcare facilities are ex-
posed to (external) auditing and benchmarking, often using
quality indicators [15–17]. Especially healthcare insurances,
policy makers (government) and patient organizations are im-
portant actors. The USA and UK have both introduced public
reporting as a tool to improve the quality of care. National
institutes as the National Quality Forum and the Dr Foster
Health focus on delivering healthcare information to the pub-
lic, for example, by providing a hospital guide to the public
including information on waiting times, length of stay, and
mortality rates for several surgical procedures [18].
In the Netherlands, a national initiative of transparency in
hospital care started in 2008, raised and funded by the gov-
ernment (Visible Care program). The aim of this initiative was
to increase transparency by providing insight into the quality
of healthcare and enabling healthcare providers to report on
actually applied diagnostics and delivered therapy and follow-
up. Quality indicators were developed and measured for over
100 disease entities, including malignant lymphoma.
This study outlines the differences in quality of delivered
NHL care in the Netherlands between 2007 and 2011 and to
what extend this was influenced by the Visible Care program.
Materials and methods
Study design and population
Data from two observational studies were used to investigate
the natural course of delivered quality of NHL care and the
influence of the Visible Care program. First, Wennekes et al.
developed quality indicators and measured their performance
in 22 Dutch hospitals by including 348 patients diagnosed
with NHL between 2006 and 2007 [14]. The quality indicators
were derived from evidence-based guidelines and developed
by an expert panel using the systematic RAND-modified
Delphi method [19]. The main goal was to provide insight
into guideline adherence for the most important processes
and structures of NHL care. Second, baseline measurements
of the Perineal Assessment and Repair Longitudinal (PEARL)
study [20], a cluster randomized controlled trial (cRCT), also
assessed indicator performance in 19 Dutch hospitals and ran-
domly included 423 patients diagnosed with NHL between
2010 and 2011. Patients eligible for both studies were defined
as patients diagnosed with a mature B-, T-, or NK-cell neo-
plasm and older than 18 years at diagnosis. Patients with mul-
tiple myeloma or cutaneous lymphoma or presenting with
chronic leukemia were excluded.
Data collection
For the PEARL study, trained registration employees collect-
ed data from medical records for the quality indicators. A
digital registration form was accomplished in collaboration
with the Comprehensive Cancer Centre the Netherlands
(CCC). Selection of patients took place using the cancer reg-
istry, which is part of the CCC. The CCC used the cancer
registry to make a list of potentially eligible patients in the
participating hospitals. Patients were randomly listed, after
which the first 30 patients were selected and data was collect-
ed for 20–25 patients per hospital. This cancer registry is
based on the pathology coding system of the World Health
Organization (WHO), and patients with mature B-, T-, and
NK-cell neoplasms were selected for inclusion.
Patient characteristics (gender, age, hospital region, pa-
tient preferences, comorbidities) and tumor-specific infor-
mation (morphology, stage, extra nodal disease, previous
malignancies, and lactate dehydrogenase (LD) values)
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were collected. Furthermore, dates and data about diagno-
sis (pathology, imaging techniques, blood counts), treat-
ment of NHL (type of therapy, response), and multidisci-
plinary consultation were assessed. This information was
used to determine the indicator performance scores: the
percentage of patients who received care as recommended
in the guidelines. If the indicator scores where <90 %,
improvement potential was considered to be present [21,
22]. Quality indicators for the domain diagnosis and stag-
ing, treatment and follow-up, and organization and coor-
dination were included in the indicator set (see Table 2).
The data collection method for the PEARL study (2011
dataset) is in line with the method described by Wennekes
et al. [14] (2007 dataset).
The national transparency initiative
In the context of the Visible Care program, a national
transparency initiative to provide insight into the quality
of hospital care, quality indicators for malignant lympho-
ma were developed in 2010 [23]. The purpose was to
develop quality indicators which represent the most im-
portant parts of NHL care and could be easily measured
by the hospitals themselves. All disciplines involved in
NHL care were asked to provide delegates to participate
in the development of the indicator set. The final indicator
set included indicators about Ann Arbor staging and
International Prognostic Index (IPI) scoring, performing
all required staging techniques such as bone marrow bi-
opsy and CT scans, assessing therapy response, arranging
multidisciplinary consultations, and providing all diagnos-
tic results within 4 weeks. The indicator set as developed
by Wennekes et al. [14] was used as one of the references
during the development of this Visible Care indicator set.
The implementation of the quality indicators was manda-
tory, since the program was part of new national policy.
Each year, hospitals were asked to provide the malignant
lymphoma indicator results about the previous year.
Yearly feedback was given to the hospitals by providing
anonymous results of all hospitals outlined by the hospi-
tals’ own results. All anonymous results were made pub-
lically available through the website www.zichtbarezorg.
nl, with the intention that these feedback methods would
lead to higher quality of overall NHL care. It was the
hospitals’ own responsibility in which way the yearly
audit was performed and the feedback was processed.
Wennekes et al. [14] collected data of hospital care before
the introduction of the Visible Care program, and we repeated
this assessment after the first 2 years of the program. In this
way, it was possible to provide insight into the proposed pos-
itive effect of the national transparency initiative on the quality
of delivered medical care.
Statistical analyses
Descriptive statistics were performed to get insight into the
patient characteristics of the two study populations. Quality
indicator scores were assessed for both datasets (2007 and
2011) and expressed in percentages to describe current prac-
tice. Univariate analyses (Χ2 tests) were used to test whether
differences in patient characteristics and quality indicator
scores were present between 2007 and 2011.
The relation between patient and tumor characteristics
(e.g., gender, previous malignancies, and LD value) and dif-
ferences in quality indicator scores between 2007 and 2011
was studied using univariate logistic regression analyses
(P<0.05). Factors often mentioned as reasons for non-
adherence were also included: Charlson index, performance
status, Ann Arbor stage, patient preferences, and type of lym-
phoma. Clinical relevant determinants that influenced quality
indicator scores in a univariate setting were tested as a group
using multivariate, multilevel logistic regression analyses
(odds ratios). In case of intercorrelations between characteris-
tics (>0.4), only one of the two was included in multivariate
analyses. A multilevel model was used to account for the
nested structure of the data, with individual patients nested
within hospitals. The intraclass correlation coefficient (ICC)
was calculated for each quality indicator to get insight into the
cluster effect of the hospitals. ICC values between 0 and 0.40
are found in other secondary care research [24].
Reliability of the data collection was assessed with a dupli-
cate registration of 30 records by two registration employees
in three hospitals. The reliability of the indicator scores was
calculated with a Kappa value, a statistical measure for inter-
observer agreement corrected for chance [25]. A missing
values analysis (t test) was performed to explore if more than
5 % of the data was missing and if missing values were miss-
ing completely at random (Little’s test).
All statistical analyses, except multilevel analyses, were
performed using IBM SPSS Statistics for Windows, version
20.0 (IMB Corp, Armonk, NY, USA). Multilevel analyses
were performed using SAS software system for Windows,
version 9.2 (SAS Institute Inc, Cary, NC, USA).
Results
Study population
Table 1 shows the characteristics of 348 patients of the 2007
dataset and 423 patients of the 2011 dataset. There were no
significant differences in gender, age, prevalence of NHL sub-
types, aggressiveness of the tumor, Charlson index, patient
preferences, and hospital region between the two study popu-
lations. In 2011, more patients were included with previous
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malignancies, Ann Arbor stages III–IV, and normal LD
values, compared to 2007.
Quality indicator scores
Table 2 describes the 20 quality indicator scores, corrected for
case-mix (i.e., gender, Ann Arbor stage, aggressiveness, pre-
vious malignancies, LD value, Charlson index, and hospital
region) and the nested structure of the data (multilevel analy-
sis). The quality indicators were divided into three domains:
diagnosis and staging, treatment and follow-up, and organiza-
tion and coordination of care.
Diagnosis and staging In this domain, improvement is seen
for two of the seven quality indicators. Indicator scores for
execution of all recommended staging techniques (QI4) im-
proved from 26 to 43 % (OR=1.902 (1.268–2.852)), and as-
sessment of the International Prognostic Index (QI5) im-
proved from 21 to 43 % (OR=2.883 (1.675–4.961)). Two
indicators scored significantly lower in 2011 compared to
2007: diagnosis based onmorphology and immune phenotype
decreased from 99 to 96 % (QI3: OR=0.190 (0.049–0.744))
and examination of blood counts decreased from 90 to 82 %
(QI7: OR=0.576 (0.340–0.976)).
Treatment and follow-up No significant differences are seen
for the six quality indicators in this domain.
Organization and coordination of care In this domain, only
one of the seven quality indicator scores significantly im-
proved (QI17): more patients (41 %) were discussed in mul-
tidisciplinary consultations in 2011 compared to 2007 (23 %)
(OR=3.360 (2.007–5.624)).
Influence of the national transparency initiative
The six quality indicators used as initial concept for the
Visible Care quality indicators are underlined in Table 2.
Significantly increased quality indicator scores were found
for three of the six indicators incorporated in the transparency
initiative: the use of all staging techniques increased from 26
to 43 %, the assessment of the IPI from 21 to 43 %, and
patients discussed in multidisciplinary consultations from 23
to 41 % (QI4, QI5, and QI17, respectively).
The other three quality indicators included in the trans-
parency initiative did not change significantly: 80 % of
the patients was staged according to the Ann Arbor clas-
sification (QI2), 60 % had a correct evaluation after che-
motherapy (QI11), and the maximum diagnostic period of
4 weeks was realized in about half of the patients (QI19).
Two of the 14 quality indicators that were not included in
the Visible Care program showed significantly decreased
scores (QI3 and QI7).
Table 1 Patient characteristics in 2007 and 2011
Characteristics 2007 (N=348) 2011 (N=423)
% 95 % CI % 95 % CI
Gender
Male 56 51–61 57 52–62
Female 44 39–49 43 38–48
Missing N=13
Mean age (years) 66±14 66±13
Charlson indexa
High risk 47 42–52 46 41–51
Low risk 53 48–58 54 49–59
Missing N=1
NHL type
DLBCL 42 37–47 46 41–51
Follicular lymphoma 23 19–27 18 14–22
Mantle-cell lymphoma 9 6–12 5 3–7
Marginal zone B-cell lymphoma 8 5–11 11 8–14
Other classification 18 14–22 20 16–24
Tumor type
Aggressive 61 56–66 60 55–65
Indolent 39 34–44 40 35–45
Ann Arbor stage*
I or II 44 38–50 32 27–37
III or IV 56 50–62 68 63–73
Unknown N=2 N=14
Not applicable N=39 N=14
Extranodal disease
Yes 58 52–64 61 56–66
No 42 36–48 39 34–44
Missing N=42 N=1
Previous malignancies*
No (NHL is first malignancy) 91 88–94 83 79–87
Yes 9 6–12 17 13–21
Missing N=1
Normal LD value*
Yes 20 16–24 56 51–61
No 80 76–84 44 39–49
Missing N=32
Patient’s preferences
Objections 6 4–8 6 4–8
No objections 94 92–96 94 92–96
Missing N=1 N=1
Hospital region
North 53 48–58 45 40–50
East 25 20–30 27 23–31
South 22 18–26 28 24–32
DLBCL diffuse large B-cell lymphoma, LD lactate dehydrogenase
*Patient characteristic significantly different (P<0.05) between 2007 and
2011
aWeighted comorbidity index combined with age
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Statistics
The mean ICC was 0.14 (range 0.005–0.33), which was cal-
culated for all quality indicators to account for clustering. The
reproducibility of the data collected for the indicator scores in
2011 was good: the average kappa value was 0.8 (range 0.4–
1.0; 87 % ≥0.6). This indicates an overall good agreement
between the registration employees. For the 2007 dataset, re-
producibility was also good [14]. Missing value analysis
showed overall less than 5 % missing data in the overall
dataset (2007 and 2011). The factor Bperformance status^
was excluded from analysis because it was missing for most
of the cases (80 %). Quality indicator 13 had 10 % missing
values; however, these were missing completely at random
(MCAR, P=0.771).
Discussion
In this study, we provided insight into the differences in qual-
ity of delivered NHL care in the Netherlands between 2007
and 2011, taking into account the Visible Care program. The
data indicated that quality of delivered NHL care improved at
a few points, but also showed a greater need for improvement
for several quality indicators. Indicator scores that decreased
significantly included assessment of immune phenotype for
diagnosis and full examination of blood counts. However,
significant improvement was shown for execution of all rec-
ommended staging techniques, assessment of the IPI, and
multidisciplinary discussion of patients.
Quality indicators included in the Visible Care program
concerning malignant lymphoma were developed and pub-
lished in 2010. The main goal of this program was to increase
transparency of the Dutch hospital care, for which publically
available data were required. This could have been a major
incentive for hospitals to meet the quality indicators and thus
improve their NHL care (if necessary). It is noticeable that the
quality indicators with increased scores (QI4, QI5, and QI17)
between 2007 and 2011 were all included in the national ini-
tiative, which implies a positive effect of the program.
However, other (local) initiatives or international study results
were not taken into account in our analysis. For example, the
added value of discussing all oncology patients during multi-
disciplinary consultations has been an increasing point of in-
terest the past years, which could have influenced our results.
Quality indicator scores that significantly decreased be-
tween the two measurements included items about pathology
diagnosis based on immune phenotype (QI3) and examination
of leukocyte differentiation during blood analyses (QI7).
Despite these decreases, the scores were still between 80 and
100 %, which indicates good performance and only a small
improvement potential. Improvement potential is often
assigned to indicator scores below 90 % [21, 22], since higher
scores might not be feasible due to case-mix factors as high
age, many comorbidities, and patient preferences. It can there-
fore be argued if the significantly decreased scores seen for the
two quality indicators are clinically relevant.
Between 2007 and 2011, there were no large changes in
guideline recommendations for NHL care in the Netherlands,
besides the addition of a recommendation to use
fluorodeoxyglucose-positron emission tomography (FDG-
PET) scans for determining therapy response [26, 27]. Using
CT scanning, location and size in millimeters should be doc-
umented, which is not necessary when a FDG-PET scan is
done, since it is based on color intensity instead of size. This
could possibly explain the decreasing trend observed in the
quality indicator concerning lesions documented in radiology
reports after therapy (QI10 67 to 58 %, not significant). Based
on our datasets, we determined that FDG-PET (CT-)scans
were used more often for evaluation after chemotherapy in
2011 (63 %) compared to 2007 (29 %, P<0.001).
Another decreasing trend was seen providing all diagnostic
results within 4 weeks after the first visit to the hospital (QI19
56 to 49 %, not significant). A factor that may play a role is
referral of patients between and within hospitals, which in-
creased from 51 % in 2007 to 64 % in 2011 (P<0.001). A
possible explanation for this might be the increasing burden
on the healthcare system, caused by the growing needs of
patients. Although this decreasing trend is not significant,
and therefore subject to chance, providing all diagnostic re-
sults within 4 weeks might be worth arguing because of its
clinical importance concerning prognosis and start of treat-
ment for patients diagnosed with NHL.We believe that longer
waiting times could result into poorer prognosis for patients,
which is already known for patients with head and neck cancer
[28]. Furthermore, short waiting times are valuable for the
level of patient centeredness of hospitals, of which the impor-
tance has grown considerably.
To our knowledge, this is the first study that focused on
providing insight into the differences in time in quality of
delivered NHL care and evaluated the effect of a national
transparency initiative. Besides the present study and
Wennekes et al.’s [14], only a few other studies conducted
research on quality of NHL care, focusing on parts of the care
process such as staging and treatment [12, 13, 29], or follow-
up care [30]. In line with our study, they showed that the
quality of NHL care is not yet optimal, compared to the rec-
ommended care as described in evidence-based guidelines.
Much research has been conducted concerning public
reporting, with widely varying results. However, the effect
of performance data on improvement of quality of care is less
often studied, and if so, mostly focuses on mortality rates [31].
A study by Lamb et al. [32] explored the 5-year impact of
voluntary public reporting on physician groups and showed
improvement for ambulatory care measures. Our results are in
accordance with these studies; however, we were able to
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provide insight into the quality of care for several measures
not included in the public reporting as well. This provided the
unique opportunity to examine the effect of public reporting,
as done within the Visible Care program, on total quality of
NHL care.
Data collection for observational studies included was per-
formed by independent, trained registration employees. In dai-
ly practice or public reporting programs, professionals them-
selves are often responsible for the data collection, which
might introduce bias as they are involved as stakeholders.
Our data collection showed also high reproducibility between
the registration employees, indicating good competency and
reliable data collection.
There are also some limitations to this study. Firstly, the
hospitals included for data collection in 2011 are not
completely identical to those included in 2007: 15 hospitals
participated in both measurements, 11 hospitals either in 2007
or 2011. However, no distinct differences were found in indi-
cator scores when the non-overlapping hospitals were left out
of the analyses. Together with a relatively large study popula-
tion (N=771), we believe that both datasets are representative
for hospitals in the Netherlands.
Secondly, we did not have insight into possible local
improvement initiatives of the participating hospitals be-
tween 2007 and 2011, which makes it difficult to link
the Visible Care program as direct and only attribute to
the changes seen in some quality indicators of NHL
care. One influencing factor could be that high room
for improvement rates were seen for four of the six
quality indicators included in this program (<30 %
scores, 2007 dataset). It can be argued that, in general,
quality indicators with low scores are easier to improve
than those with higher scores. Hospitals, participated in
the 2007 study, received general feedback on their per-
formance as a group and as hospital region, which
might have triggered some local improvement initia-
tives. However, improving NHL care was not the aim
of the 2007 study, and no concrete improvement initia-
tives are known based on the provided feedback. This
result is supported by a Cochrane review, which showed
that the effect of audit and feedback on improvement is
usually small [33].
In summary, during the 4-year period between 2007 and
2011, we found little improvement in overall quality of NHL
care. Improvement potential as found in 2007 remained for all
quality indicators in 2011, unless some significant increased
indicator scores. Based on our results, we can conclude that a
national initiative as the Visible Care program might not have
enough power to improve hospital care for NHL in general,
but might provide a first step towards a more improvement-
oriented hospital care. Improvement strategies tailored to the
suboptimal quality of NHL care might be a rational step to
develop and test in a randomized setting.
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